Research News
Using a molecule found in green tea, an Alzheimer's Disease Research-funded team of biochemists has identified new molecules that can destroy protein tangles in the brain linked to Alzheimer's and related brain diseases.
BrightFocus Foundation’s newly released research portfolios highlight the more than 250 active grants across our Alzheimer’s Disease Research, National Glaucoma Research, and Macular Degeneration Research programs in pursuit of discovering cures for diseases of mind and sight.
A new BrightFocus-funded clinical trial is one of the first to study the benefits of exercise in protecting brain health specifically among older African Americans.
The U.S. Food and Drug Administration in November granted Breakthrough Therapy designation for a new treatment that could slow the progression of geographic atrophy, an advanced and severe form of dry age-related macular degeneration that can lead to permanent vision loss.
Nearly 20 million adults in the U.S. have some form of age-related macular degeneration, almost double the previous estimate of 11 million people, according to a new report. Learn why.
A new blood test that could facilitate a more accurate diagnosis of Alzheimer’s during the initial phases of the disease is on the way—rooted in critical early support from Alzheimer’s Disease Research, a program of BrightFocus Foundation. Catching the disease as soon as possible offers affected individuals the greatest gift of all—more time to spend with loved ones and explore disease management and treatment options.
A team of BrightFocus-funded scientists has proposed a new explanation and possible new target for treatment in glaucoma that’s unrelated to the common culprit of eye pressure.
David Liao, MD, offers insights into managing and understanding AMD and what forthcoming FDA approval could mean for treatment.
Clinical trial results released Nov. 29 for lecanemab, a drug targeting early Alzheimer’s disease, reported a moderate slowing of cognitive decline in patients by 25% through the removal of amyloid-beta (Aβ) in the brain.
If approved, the drug pegcetacoplan would become the first-ever treatment in the U.S. for geographic atrophy, a blinding and advanced form of age-related macular degeneration.
